quadgram

This is a table of type quadgram and their frequencies. Use it to search & browse the list to learn more about your study carrel.

quadgram	frequency
for the treatment of	271
severe acute respiratory syndrome	261
in patients with covid	203
display the preprint in	191
granted medrxiv a license	191
has granted medrxiv a	191
a license to display	191
to display the preprint	191
medrxiv a license to	191
who has granted medrxiv	191
license to display the	191
acute respiratory syndrome coronavirus	188
the copyright holder for	179
copyright holder for this	179
the treatment of covid	172
is the author funder	170
the preprint in perpetuity	154
in the treatment of	152
holder for this preprint	143
made available under a	141
it is made available	141
is made available under	141
license it is made	139
international license it is	139
of cq and hcq	129
under a is the	111
available under a is	111
a is the author	111
for this preprint this	108
preprint this version posted	108
this preprint this version	108
of severe acute respiratory	107
was not certified by	91
certified by peer review	91
not certified by peer	91
hydroxychloroquine in patients with	89
hospitalized patients with covid	84
in hospitalized patients with	81
acute respiratory distress syndrome	77
which was not certified	75
efficacy and safety of	74
j o u r	73
o u r n	73
r n a l	73
p r o o	73
a l p r	73
r o o f	73
n a l p	73
u r n a	73
l p r e	73
of hydroxychloroquine in patients	71
as a treatment of	71
a treatment of covid	70
of chloroquine and hydroxychloroquine	69
systematic review and meta	69
patients with severe covid	67
azithromycin as a treatment	67
patients treated with hcq	67
and azithromycin as a	67
hydroxychloroquine and azithromycin as	67
the use of hcq	67
in vitro antiviral activity	63
hydroxychloroquine and azithromycin in	63
in patients with severe	63
results of an open	63
the treatment of severe	62
or in combination with	61
a randomized clinical trial	61
treatment of severe acute	60
alone or in combination	60
of hydroxychloroquine and azithromycin	59
a systematic review and	59
middle east respiratory syndrome	58
efficacy of hydroxychloroquine in	57
en pacientes con covid	56
hydroxychloroquine for the treatment	56
of hydroxychloroquine for the	55
study of hydroxychloroquine in	54
optimized dosing design of	53
and projection of optimized	53
design of hydroxychloroquine for	53
activity and projection of	53
of optimized dosing design	53
vitro antiviral activity and	53
projection of optimized dosing	53
dosing design of hydroxychloroquine	53
antiviral activity and projection	53
with systemic lupus erythematosus	52
patients with coronavirus disease	52
this version posted june	52
combination of hydroxychloroquine and	52
hcq with or without	52
the efficacy and safety	51
article is protected by	49
of hydroxychloroquine and chloroquine	49
this article is protected	49
with or without azithromycin	49
is protected by copyright	49
critically ill patients with	48
in the context of	48
chloroquine and hydroxychloroquine in	48
in systemic lupus erythematosus	47
in combination with azithromycin	45
hydroxychloroquine in hospitalized patients	44
cq and hcq are	43
of hydroxychloroquine in hospitalized	43
in treatment of covid	43
at the time of	43
with hydroxychloroquine and azithromycin	42
for treatment of covid	42
treatment of patients with	42
patients with rheumatoid arthritis	42
cq and hcq in	41
results of a randomized	41
in the hcq group	40
the antiviral effects of	40
effective in inhibiting sars	40
toxic derivative of chloroquine	39
mortality in patients with	39
is effective in inhibiting	39
chloroquine effectively inhibit the	39
effectively inhibit the recently	39
mechanisms of action of	39
remdesivir and chloroquine effectively	39
less toxic derivative of	39
recently emerged novel coronavirus	39
on the other hand	39
and chloroquine effectively inhibit	39
inhibit the recently emerged	39
a less toxic derivative	39
the recently emerged novel	39
in patients with rheumatoid	38
of patients with covid	38
in vitro and in	37
pneumonia in clinical studies	37
in patients with sars	37
associated pneumonia in clinical	37
efficacy in treatment of	37
has shown apparent efficacy	37
east respiratory syndrome coronavirus	37
shown apparent efficacy in	37
mechanism of action of	37
apparent efficacy in treatment	36
preprint the copyright holder	36
this this version posted	36
holder for this this	36
food and drug administration	36
chloroquine phosphate has shown	36
for this this version	36
this version posted november	36
phosphate has shown apparent	36
both cq and hcq	35
mg twice daily for	34
of a randomized clinical	34
hydroxychloroquine with or without	34
this version posted may	33
patients with systemic lupus	33
ill patients with covid	33
a systematic review of	33
observational study of hydroxychloroquine	33
with severe acute respiratory	33
in the control group	32
vitro and in vivo	32
a retrospective cohort study	32
of action of hydroxychloroquine	31
between the two groups	31
has been shown to	31
interval in patients with	30
the world health organization	30
was associated with a	30
safety and efficacy of	30
and azithromycin in covid	30
patients treated with hydroxychloroquine	29
of a combination of	29
the intensive care unit	29
an increased risk of	29
of critically ill patients	29
of cq or hcq	29
in patients treated with	29
review of the literature	29
increase the risk of	28
cq and hcq have	28
in the absence of	28
of hospitalized patients with	28
systematic review of the	28
with the combination of	28
association of treatment with	28
qt interval in patients	28
the effect of hcq	28
with at least a	28
with the use of	28
systematic reviews and meta	28
as well as the	28
at least a six	28
patients with at least	28
effect of a combination	28
of treatment with hydroxychloroquine	28
of hcq and cq	27
in critically ill patients	27
hospital mortality in patients	27
at a dose of	27
in a patient with	27
the severe acute respiratory	27
antiviral effects of chloroquine	27
no significant difference in	27
in the united states	27
a combination of hydroxychloroquine	27
en los pacientes con	27
azithromycin in patients with	26
the efficacy of hcq	26
microbiological effect of a	26
clinical and microbiological effect	26
with hydroxychloroquine or azithromycin	26
and microbiological effect of	26
the use of cq	26
time to clinical improvement	26
hydroxychloroquine or azithromycin with	26
and azithromycin in patients	26
a potent inhibitor of	26
this version posted july	26
no evidence of rapid	26
treatment with hydroxychloroquine or	26
of rapid antiviral clearance	25
the combination of hydroxychloroquine	25
evidence of rapid antiviral	25
in new york state	25
antiviral clearance or clinical	25
clinical benefit with the	25
in the management of	25
clearance or clinical benefit	25
or clinical benefit with	25
in patients with systemic	25
there was no significant	25
it is important to	25
benefit with the combination	25
rapid antiviral clearance or	25
or azithromycin with in	25
clinical efficacy of hydroxychloroquine	24
a pilot observational study	24
of patients with coronavirus	24
of qt interval prolongation	24
pacientes con sospecha o	24
potent inhibitor of sars	24
action of hydroxychloroquine and	24
associated with use of	24
combination of hcq and	24
used for the treatment	24
de pacientes con covid	23
a dose of mg	23
on the use of	23
was not associated with	23
have been shown to	23
se recomienda no utilizar	23
for cq and hcq	23
for the management of	23
the combination of hcq	23
a randomized controlled trial	22
effect of hcq on	22
of sars coronavirus infection	22
paciente con sospecha o	22
sars coronavirus infection and	22
effects of chloroquine on	22
is a potent inhibitor	22
in the case of	22
of patients infected with	22
chloroquine and hydroxychloroquine as	21
patients testing positive for	21
the use of these	21
with use of hydroxychloroquine	21
of these drugs in	21
used in the treatment	21
and systemic lupus erythematosus	21
which was not peer	21
the qt interval in	21
to moderate coronavirus disease	21
use of cq hcq	21
hydroxychloroquine in treatment of	21
was found to be	21
risk of qt interval	21
of hydroxychloroquine in treatment	21
inhibitor of sars coronavirus	21
a pilot study of	21
chloroquine is a potent	21
pilot study of hydroxychloroquine	21
coronavirus infection and spread	21
mild to moderate coronavirus	21
mainly mild to moderate	20
on the efficacy and	20
hydroxychloroquine in the treatment	20
states veterans hospitalized with	20
hydroxychloroquine usage in united	20
case series of patients	20
with mild to moderate	20
interval prolongation associated with	20
of hydroxychloroquine usage in	20
patients with mainly mild	20
the safety and efficacy	20
en el grupo de	20
united states veterans hospitalized	20
in patients with mainly	20
chloroquine for the treatment	20
patients hospitalized with severe	20
outcomes of hydroxychloroquine usage	20
usage in united states	20
in united states veterans	20
series of patients with	20
under a author funder	20
in treatment of patients	20
veterans hospitalized with covid	20
available under a author	20
infection treated with hydroxychloroquine	20
of hydroxychloroquine with or	20
the antiviral activity of	20
compared to the control	20
with mainly mild to	20
therapy for patients hospitalized	19
los pacientes con covid	19
effect of hydroxychloroquine in	19
diphosphate as adjunctive therapy	19
it should be noted	19
torsade de pointes in	19
the treatment of sars	19
azithromycin among hospitalized patients	19
that the use of	19
use of hydroxychloroquine with	19
hcq was associated with	19
concomitant azithromycin among hospitalized	19
in combination with other	19
hcq in patients with	19
hospitalized with severe acute	19
in vitro in vitro	19
is one of the	19
or without concomitant azithromycin	19
qt interval prolongation associated	19
testing positive for coronavirus	19
chloroquine diphosphate as adjunctive	19
with or without concomitant	19
among hospitalized patients testing	19
prolongation associated with use	19
adjunctive therapy for patients	19
of systemic lupus erythematosus	19
chloroquine on viral infections	19
treated with hydroxychloroquine azithromycin	19
hospitalized patients testing positive	19
of chloroquine on viral	19
without concomitant azithromycin among	19
as adjunctive therapy for	19
a higher risk of	19
and hydroxychloroquine in the	19
for patients hospitalized with	19
studies have shown that	19
of cq hcq in	18
patients hospitalized for covid	18
an old drug against	18
preferred reporting items for	18
of torsade de pointes	18
patients with mild to	18
of the qt interval	18
to the control group	18
followed by mg twice	18
en el paciente con	18
mild to moderate covid	18
cq and or hcq	18
effect of high vs	18
risk of qtc prolongation	18
patients hospitalized with covid	18
of chloroquine diphosphate as	18
in vitro activity against	18
in patients hospitalized for	18
use of hcq in	18
positive for coronavirus disease	18
no conflict of interest	18
not included in the	17
patients infected with sars	17
hydroxychloroquine as postexposure prophylaxis	17
of patients with common	17
use of cq and	17
was no significant difference	17
with common coronavirus disease	17
treated with hcq and	17
of novel coronavirus pneumonia	17
vitro in vitro antiviral	17
should be noted that	17
hcq in the treatment	17
use of these drugs	17
a trial of lopinavir	17
in adults hospitalized with	17
treated with hydroxychloroquine and	17
in the present study	17
with or without a	17
of action of cq	17
hcq alone or in	17
mg per day for	17
an intensive care unit	17
the use of hydroxychloroquine	17
a case series of	17
doses of chloroquine diphosphate	17
of hcq in covid	17
low doses of chloroquine	17
of chloroquine for the	17
in vitro inhibition of	17
cardiac complications attributed to	17
the viral shedding duration	17
patients with common coronavirus	17
of high vs low	16
were included in the	16
no reuse allowed without	16
treatments for coronavirus disease	16
postexposure prophylaxis for covid	16
ritonavir in adults hospitalized	16
use of chloroquine and	16
as postexposure prophylaxis for	16
m a n u	16
r i p t	16
recomienda no utilizar de	16
n u s c	16
randomized trial of hydroxychloroquine	16
treatment of novel coronavirus	16
the treatment of patients	16
a randomized trial of	16
high vs low doses	16
u s c r	16
need for mechanical ventilation	16
emergency use authorization for	16
mg daily for days	16
for the use of	16
hcq for the treatment	16
reuse allowed without permission	16
on the first day	16
a n u s	16
c r i p	16
hospitalized with severe covid	16
in vero e cells	16
to the intensive care	16
a multinational registry analysis	16
s c r i	16
vs low doses of	16
a total of patients	16
in the treatment group	16
twice daily for days	16
in a case series	15
of the included studies	15
or without a macrolide	15
significant difference in the	15
para el manejo de	15
it has been reported	15
in patients hospitalized with	15
disease control and prevention	15
has been associated with	15
a retrospective analysis of	15
patients with novel coronavirus	15
patients who received hcq	15
with or without az	15
of hcq and rfifn	15
one of the most	15
by mg twice daily	15
trial of hydroxychloroquine as	15
been shown to be	15
longest daily measured qtc	15
pharmacologic treatments for coronavirus	15
to be associated with	15
systemic lupus erythematosus and	15
either cq or hcq	15
the corrected qt interval	15
effects of cq and	15
has been reported to	15
for chloroquine and hydroxychloroquine	15
for disease control and	15
such as systemic lupus	15
adults hospitalized with severe	15
on the basis of	15
a systematic review on	15
of hydroxychloroquine as postexposure	15
as a result of	15
the mechanism of action	15
qt intervals in a	14
insights on the antiviral	14
chloroquine with or without	14
or chloroquine with or	14
as shown in figure	14
randomized clinical trial hydroxychloroquine	14
in the presence of	14
intervals in a case	14
mode of action of	14
what to expect for	14
attributed to chloroquine and	14
reporting items for systematic	14
patients were treated with	14
and torsade de pointes	14
hydroxychloroquine alone or in	14
without a macrolide for	14
as systemic lupus erythematosus	14
a favor o en	14
of qt intervals in	14
in the risk of	14
new insights on the	14
the effect of hydroxychloroquine	14
qt interval prolongation and	14
of chloroquine against coronavirus	14
of hcq in the	14
has been reported that	14
on the antiviral effects	14
el paciente con sospecha	14
analysis of cases in	14
assessment of qt intervals	14
dose of mg twice	14
entry into host cells	14
de los pacientes con	14
to expect for covid	14
complications attributed to chloroquine	14
the standard of care	14
the end of the	14
effects of chloroquine against	14
with cq and hcq	14
favor o en contra	14
hydroxychloroquine or chloroquine with	14
of cases in marseille	14
followed by mg daily	14
patients with hydroxychloroquine and	14
the use of chloroquine	14
it has been shown	14
for patients with severe	14
the fact that the	14
macrolide for treatment of	14
and severe acute respiratory	14
retrospective analysis of cases	14
en pacientes con sospecha	14
is associated with a	14
to chloroquine and hydroxychloroquine	14
a macrolide for treatment	14
combination with azithromycin in	14
depends on ace and	13
comparative study using routine	13
of hcq in patients	13
pacientes en el grupo	13
with hydroxychloroquine alone or	13
with azithromycin in an	13
of middle east respiratory	13
in patients with mild	13
in light of the	13
and safety of chloroquine	13
in intensive care unit	13
no significant difference between	13
patients with severe acute	13
using routine care data	13
en el tratamiento de	13
treatment of coronavirus disease	13
patients infected with novel	13
with novel coronavirus in	13
el uso de la	13
of the immune system	13
items for systematic reviews	13
effect of chloroquine on	13
patients who did not	13
rheumatoid arthritis and systemic	13
on ace and tmprss	13
has been shown that	13
pneumonia who require oxygen	13
observational comparative study using	13
infected with novel coronavirus	13
of chloroquine and hcq	13
of patients treated with	13
chloroquine and hydroxychloroquine for	13
it is possible that	13
in an intensive care	13
in a mouse model	13
treated with hydroxychloroquine alone	13
efficacy of hcq in	13
as a treatment for	13
and hcq have been	13
vitro activity against sars	13
patients with rheumatic diseases	13
study using routine care	13
associated with qtc prolongation	13
arthritis and systemic lupus	13
for patients with covid	13
which this version posted	13
associated with an increased	13
and hcq in covid	13
by mg daily for	13
azithromycin in an intensive	13
for systematic reviews and	13
hydroxychloroquine and azithromycin on	13
effect of hydroxychloroquine on	13
cq or hcq with	13
of hydroxychloroquine and its	13
fuerte a favor fundamento	13
tmprss and is blocked	12
with a combination of	12
with acute respiratory distress	12
hospitalized patients with severe	12
hcq in combination with	12
se puede emitir una	12
and safety of hcq	12
clinical studies hydroxychloroquine and	12
characteristics of coronavirus disease	12
loading dose of mg	12
pharmacokinetics of hydroxychloroquine in	12
clinical characteristics of coronavirus	12
el manejo de la	12
that cq and hcq	12
prolongation and torsade de	12
in patients with coronavirus	12
a review of the	12
clinical features of patients	12
and the risk of	12
treatment with hydroxychloroquine and	12
hydroxychloroquine as available weapons	12
a large number of	12
and risk factors for	12
associated with lower mortality	12
national institutes of health	12
important to note that	12
that there was no	12
ace and tmprss and	12
features of patients infected	12
the time to clinical	12
patient with systemic lupus	12
human immunodeficiency virus type	12
and safety of cq	12
cell entry depends on	12
day followed by mg	12
clinically proven protease inhibitor	12
or without azithromycin in	12
through the inhibition of	12
unidad de cuidados intensivos	12
early treatment of covid	12
available weapons to fight	12
either alone or in	12
severe acute respiratory distress	12
by a clinically proven	12
for the novel coronavirus	12
and is blocked by	12
lupus erythematosus and rheumatoid	12
is blocked by a	12
with a total of	12
pharmacokinetics of hydroxychloroquine and	12
of chloroquine or hydroxychloroquine	12
the management of covid	12
and tmprss and is	12
novel coronavirus in wuhan	12
entry depends on ace	12
of intubation or death	12
a clinically proven protease	12
studies hydroxychloroquine and azithromycin	12
patients in the hcq	12
blocked by a clinically	12
of coronavirus disease in	12
lower than that of	12
the treatment of malaria	12
of mg twice daily	12
has also been reported	12
were treated with hcq	12
and hydroxychloroquine as available	12
for each of the	12
weapons to fight covid	12
no se puede emitir	12
erythematosus and rheumatoid arthritis	12
in clinical studies hydroxychloroquine	12
the preferred reporting items	12
as available weapons to	12
with cq or hcq	11
in the control arm	11
systematic review on the	11
risk factors for mortality	11
terminal glycosylation of ace	11
of cq and or	11
chronic obstructive pulmonary disease	11
the treatment of novel	11
was approved by the	11
at the same time	11
toxicity and pharmacokinetics of	11
animal toxicity and pharmacokinetics	11
hcq and cq in	11
did not show any	11
los pacientes con sospecha	11
a combination of hcq	11
drugs for the treatment	11
infection in vitro in	11
in the intensive care	11
hcq and cq have	11
antiviral activity of hcq	11
to be effective in	11
con el fin de	11
the authors declare no	11
associated with qt prolongation	11
trial no evidence of	11
trial clinical and microbiological	11
azithromycin on the corrected	11
use of remdesivir for	11
a report of cases	11
results showed that the	11
associated with a reduction	11
by hcq and cq	11
these drugs in the	11
on the corrected qt	11
risk of bias in	11
the absence of a	11
insights into the antiviral	11
safety of hcq in	11
en pacientes con sdra	11
review on the efficacy	11
characteristics and outcomes of	11
length of hospital stay	11
and pharmacokinetics of hydroxychloroquine	11
and congestive heart failure	11
been reported to be	11
as compared to the	11
and treatment of covid	11
and azithromycin on the	11
de los pacientes que	11
the institutional review board	11
it is difficult to	11
using routinely collected data	11
new insights into the	11
alone and in combination	11
of hcq with or	11
is mediated by the	11
hospitalized patients with novel	11
pharmacokinetics of hydroxychloroquine sulfate	11
corrected qt interval in	11
and efficacy of hcq	11
combination with other drugs	11
mg twice a day	11
hydroxychloroquine and chloroquine during	11
into the antiviral effects	11
with the glycosylation of	11
patients with acute respiratory	10
there was a significant	10
treatment of severe covid	10
compassionate use of remdesivir	10
label nonrandomized clinical trial	10
a loading dose of	10
hcq was found to	10
con el uso de	10
no conflicts of interest	10
centers for disease control	10
chloroquine and hydroxychloroquine are	10
from patients with pneumonia	10
a key role in	10
american college of cardiology	10
qt interval prolongation in	10
use of hcq was	10
risk of adverse events	10
such as rheumatoid arthritis	10
a study using routinely	10
is important to note	10
of adult inpatients with	10
inhibits the replication of	10
to emulate a target	10
factors for mortality of	10
safety of chloroquine for	10
a novel coronavirus from	10
use of hcq and	10
mortality of adult inpatients	10
available under a perpetuity	10
trial efficacy of hydroxychloroquine	10
were found to be	10
of hcq and azithromycin	10
a treatment for covid	10
final de la vida	10
the activation of the	10
united states food and	10
the ph of the	10
adult inpatients with covid	10
outcomes in patients with	10
the qt interval and	10
routinely collected data to	10
for mortality of adult	10
bioavailability of hydroxychloroquine tablets	10
results of a study	10
course and risk factors	10
effects of cq hcq	10
of both cq and	10
and azithromycin in the	10
states food and drug	10
evidence of clinical efficacy	10
de pointes in patients	10
a significant effect of	10
the risk of qtc	10
emulate a target trial	10
treatment of systemic lupus	10
at the beginning of	10
with human immunodeficiency virus	10
data to emulate a	10
collected data to emulate	10
with a code for	10
prolongation of the qt	10
randomized clinical trial clinical	10
of convalescent plasma therapy	10
study using routinely collected	10
clinical trial clinical and	10
of clinical efficacy of	10
by the fact that	10
and the use of	10
cq and hcq is	10
of hcq was associated	10
in patients with diabetes	10
the results of the	10
clinical course and risk	10
utilizar de forma rutinaria	10
of human immunodeficiency virus	10
no evidence of clinical	10
mortality in hospitalized patients	10
the stable binding of	10
in the prevention of	10
no significant differences in	10
than that of cq	10
that they have no	10
of a study using	10
cq and hcq with	10
no utilizar de forma	10
qt prolongation and refractory	9
with pneumonia in china	9
the replication of sars	9
mg three times daily	9
the strength of the	9
inhibition of severe acute	9
recommendation to examine the	9
used to treat covid	9
use of hcq for	9
into the host cell	9
in the number of	9
is an urgent need	9
infection with oxygen requirement	9
showed no significant difference	9
patients with pneumonia in	9
treated with hcq alone	9
the effect of cq	9
the antiviral effect of	9
than that of hcq	9
on the efficacy of	9
hcq and cq can	9
clinical trial efficacy of	9
the mrna expression of	9
respiratory syndrome coronavirus by	9
prolongation and refractory ventricular	9
in the form of	9
has been demonstrated that	9
hcq mg twice daily	9
syndrome coronavirus by chloroquine	9
was associated with an	9
the results of this	9
and in combination with	9
the frequency of lqt	9
cq has been shown	9
an urgent need for	9
risk of cardiovascular death	9
hcq has been used	9
in patients with rheumatic	9
this version posted april	9
the treatment of coronavirus	9
a significant reduction in	9
effects of hydroxychloroquine on	9
of patients in the	9
influenza a h n	9
of the original paper	9
been shown to inhibit	9
and outcomes of critically	9
effects of hcq on	9
of hydroxychloroquine in preventing	9
a recommendation to examine	9
at higher risk of	9
diagnosis and treatment of	9
coronavirus disease in china	9
are presented in table	9
preventing infection and progression	9
combination in patients hospitalized	9
the effect of chloroquine	9
characteristics of hospitalized patients	9
use for the treatment	9
to the lack of	9
of crh in the	9
in preventing infection and	9
coronavirus from patients with	9
included in the study	9
of these drugs strongly	9
expression of crh in	9
vitro inhibition of severe	9
there is an urgent	9
effects of chloroquine and	9
significant difference between the	9
use associated with qt	9
of type i ifn	9
hydroxychloroquine is associated with	9
with an ec of	9
hydroxychloroquine in patients hospitalized	9
positive effect of hcq	9
hydroxychloroquine use associated with	9
the american college of	9
may be due to	9
treated with hcq or	9
of qtc prolongation and	9
of cq hcq on	9
in patients with acute	9
to assess the efficacy	9
chronic hydroxychloroquine use associated	9
the united states food	9
are shown in figure	9
clinical characteristics of hospitalized	9
a wide range of	9
the time of writing	9
difference between the two	9
been shown to have	9
in the pbs group	9
the combination of these	9
due to the lack	9
of action of chloroquine	9
the effectiveness of hcq	9
and combination in patients	9
and tumor necrosis factor	9
prophylaxis and treatment of	9
of these two drugs	9
did not result in	9
novel coronavirus from patients	9
in acute respiratory distress	9
from the coronavirus disease	9
the risk of qt	9
antiviral activity of cq	9
side effect of hcq	9
coronavirus replication in cell	9
a total of participants	9
to severe acute respiratory	9
desde el inicio de	9
en el manejo de	9
outcomes of critically ill	9
chloroquine in the treatment	9
fuera de la uci	9
for critically ill patients	9
large volume of distribution	9
has been found to	9
to examine the effect	9
in addition to the	9
risk of intubation or	9
of remdesivir for patients	9
was defined as a	9
side effects of hcq	9
hydroxychloroquine in preventing infection	9
an increase in the	9
with qt prolongation and	9
it has been demonstrated	9
systemic lupus erythematosus patients	9
action of cq hcq	9
effect of hcq mono	9
remdesivir for patients with	9
respiratory syndrome coronavirus infection	9
examine the effect of	9
patients infected with covid	9
cq and hcq for	9
patients treated with cq	9
of hydroxychloroquine tablets in	9
studies are needed to	9
combination of these drugs	9
lpv r and hcq	9
a dosis de mg	9
those treated with hcq	9
of either cq or	8
of action of hcq	8
a systematic search and	8
in accordance with the	8
or without azithromycin and	8
the beginning of the	8
cq and hcq against	8
were more likely to	8
inhibitors of middle east	8
maps and institutional affiliations	8
the efficacy of cq	8
the longest daily measured	8
to jurisdictional claims in	8
lessons from the coronavirus	8
of the drugs in	8
during the study period	8
in line with the	8
of hcq has been	8
of human influenza a	8
declare that they have	8
was used to predict	8
mild to moderate disease	8
with or without diabetes	8
organic anion transporting polypeptide	8
levels in patients with	8
without azithromycin in mild	8
mg twice daily on	8
the food and drug	8
significant effect of drug	8
neutral with regard to	8
that the effect of	8
systemic lupus erythematosus hydroxychloroquine	8
to be effective against	8
with hcq and azithromycin	8
urgent guidance for navigating	8
efficacy of cq and	8
no utilizar de rutina	8
the use of corticosteroids	8
several clinical trials are	8
during the first trimester	8
analyses were performed using	8
in the course of	8
higher than that of	8
cq and hcq as	8
effective in the treatment	8
the results showed that	8
of hcq on the	8
and torsades de pointes	8
virus replication by chloroquine	8
prevention or treatment of	8
replication in cell culture	8
nature remains neutral with	8
with regard to jurisdictional	8
was determined to be	8
for age and gender	8
interval prolongation and torsade	8
at the end of	8
drug ivermectin inhibits the	8
entry of severe acute	8
the severity of the	8
declare no conflict of	8
patients were included in	8
of and important lessons	8
included in the meta	8
to the use of	8
and important lessons from	8
management of patients with	8
al final de la	8
mediated by the spike	8
guidance for navigating and	8
los trabajadores de la	8
and synthesis of hydroxyferroquine	8
phase iib clinical trial	8
and circumventing the qtc	8
risk of torsade de	8
for severe acute respiratory	8
on day followed by	8
remains neutral with regard	8
as well as to	8
in the setting of	8
daily dose of mg	8
were excluded from the	8
in the study by	8
is likely to be	8
use of convalescent plasma	8
by severe acute respiratory	8
the expression of crh	8
support the use of	8
was defined as the	8
for the positive effect	8
risk of adverse effects	8
anion transporting polypeptide a	8
the majority of patients	8
the present study was	8
trabajadores de la salud	8
hcq and cq are	8
characteristics of and important	8
entry into the host	8
transfer to the icu	8
into host cells through	8
with a reduction of	8
in a cohort of	8
the early phase of	8
it was shown that	8
en los pacientes que	8
novel severe acute respiratory	8
hydroxyferroquine derivatives with antimalarial	8
for treatment of sars	8
in any of the	8
all over the world	8
the lower respiratory tract	8
by gautret et al	8
total of patients were	8
association between hcq and	8
an increase in qtc	8
ivermectin inhibits the replication	8
with the exception of	8
use of this drug	8
was performed using the	8
profesionales de la salud	8
pointes in patients with	8
for navigating and circumventing	8
and reproduction in any	8
in the disease course	8
by the spike glycoprotein	8
a patient with systemic	8
design and synthesis of	8
in the early phase	8
safety of cq and	8
followed by a maintenance	8
of hydroxyferroquine derivatives with	8
claims in published maps	8
a maintenance dose of	8
that the combination of	8
d used by the	8
be used to treat	8
prevention and treatment of	8
and refractory ventricular arrhythmia	8
critically ill adults with	8
hcq and lpv r	8
adverse event reporting system	8
reproduction in any medium	8
can be used to	8
infected pneumonia in wuhan	8
despite lack of evidence	8
para el uso de	8
hydroxychloroquine in coronavirus disease	8
la toma de decisiones	8
proportion of patients with	8
used in combination with	8
of the solidarity trial	8
outcomes of patients with	8
in the experimental group	8
springer nature remains neutral	8
there is currently no	8
the rbd of sars	8
la unidad de cuidados	8
by a maintenance dose	8
cyp a and cyp	8
of the host cell	8
patients in the control	8
and sudden cardiac death	8
the context of covid	8
the pooled incidence of	8
published maps and institutional	8
fatality of critically ill	8
the small sample size	8
activity of cq hcq	8
the time of this	8
the interpretation of the	8
use of hydroxychloroquine in	8
el de los pacientes	8
effect of drug treatment	8
it was reported that	8
in a recent study	8
course of the disease	8
action of cq and	8
regard to jurisdictional claims	8
the time of the	8
important lessons from the	8
in published maps and	8
the effects of hcq	8
treatment and prophylaxis of	8
risk of qt prolongation	8
maintenance dose of mg	8
by the world health	8
inhibited by hcq and	8
navigating and circumventing the	8
una serie de casos	8
in patients receiving hcq	8
in the majority of	8
a mouse model of	8
randomized clinical trial efficacy	8
the authors declare that	8
pharmacogenomics and personalized medicine	8
evidence for the positive	8
mechanism of action and	8
of qt prolongation and	8
model was used to	8
cq or hcq in	8
and hydroxychloroquine in covid	8
synthesis of hydroxyferroquine derivatives	8
jurisdictional claims in published	8
the risk of tdp	8
use of hydroxychloroquine and	8
respiratory distress syndrome and	7
patients with moderate covid	7
patients in the treatment	7
safety results of a	7
syndrome coronavirus is mediated	7
development and validation of	7
for prophylaxis of covid	7
trial hydroxychloroquine and azithromycin	7
distribution and reproduction in	7
respiratory syndrome coronavirus replication	7
preliminary safety results of	7
in the hcq treatment	7
date with a code	7
india and other developing	7
o o f key	7
caused by severe acute	7
this is the first	7
the pharmacokinetics of hcq	7
activity of hcq and	7
of cq hcq may	7
the positive effect of	7
role of chloroquine and	7
a special reference to	7
and sudden death with	7
associated with disease severity	7
in the pathogenesis of	7
daily measured qtc after	7
due to the small	7
small number of patients	7
the clinical efficacy of	7
narrative review with a	7
en el marco de	7
the effects of cq	7
tocilizumab therapy in covid	7
on the outcome of	7
for the purpose of	7
patients with severe respiratory	7
study has several limitations	7
antimalarial and antiviral activities	7
center for disease control	7
high dose of hcq	7
and other developing countries	7
conducted to assess the	7
pneumonia outbreak associated with	7
be effective in the	7
cell transfer through dc	7
and enhanced by dendritic	7
use is associated with	7
dose of hydroxychloroquine reduces	7
coronavirus is mediated by	7
drugs in the treatment	7
on the expression of	7
no significant effect of	7
prolongation of the qtc	7
patients treated with a	7
in the original paper	7
hydroxychloroquine tablets in healthy	7
per day for days	7
chronic treatment with hcq	7
of hcq against sars	7
reference to india and	7
outbreak associated with a	7
assessing risk of bias	7
influenza a and b	7
on patients with covid	7
there has been a	7
de acuerdo con la	7
and a narrative review	7
a median of days	7
compound library identifies four	7
sobre el uso de	7
authors declare that they	7
treatment of rheumatoid arthritis	7
note springer nature remains	7
mg times day for	7
mundial de la salud	7
the use of the	7
and tocilizumab therapy in	7
the spike glycoprotein and	7
with a special reference	7
syndrome coronavirus replication in	7
were found to have	7
the chinese center for	7
short courses of chloroquine	7
for the prevention of	7
sudden death with short	7
prolonging and torsadogenic potential	7
patients with autoimmune diseases	7
twice daily on day	7
for the next days	7
associated with a new	7
was conducted to assess	7
the treatment of rheumatoid	7
chloroquine for treatment of	7
of this study was	7
have not yet been	7
effects of the combination	7
was one of the	7
of the combination of	7
hcq are weak bases	7
el inicio de los	7
results of this study	7
in patients infected with	7
a subset of patients	7
a pneumonia outbreak associated	7
randomized clinical trial a	7
respiratory syndrome coronavirus is	7
has been used for	7
in patients with a	7
and treatment of malaria	7
glycoprotein and enhanced by	7
optimization of hydroxychloroquine dosing	7
and was determined to	7
african green monkey kidney	7
systematic search and a	7
with an increased risk	7
the presence of the	7
associated with a higher	7
to india and other	7
tablets in healthy volunteers	7
death in patients with	7
also been shown to	7
proteolytic cleavage of the	7
antiviral effects on sars	7
that treatment with hcq	7
the prevention or treatment	7
dependent entry of severe	7
death with short courses	7
in addition to standard	7
a new coronavirus of	7
tool for assessing risk	7
a result of the	7
hcq or lpv r	7
potential of possible pharmacotherapies	7
combination with a macrolide	7
search and a narrative	7
a narrative review with	7
to be used in	7
was not included in	7
treatment in patients with	7
dose of hcq was	7
are summarized in table	7
adults with severe covid	7
se recomienda considerar la	7
in the use of	7
with or without azn	7
special reference to india	7
with a new coronavirus	7
and hcq are weak	7
in adult patients with	7
was significantly lower than	7
remdesivir for the treatment	7
dendritic cell transfer through	7
the safety of hcq	7
side effects of cq	7
and mortality in covid	7
treatment of rheumatic diseases	7
by dendritic cell transfer	7
post hoc analysis revealed	7
we evaluated the antiviral	7
were included in this	7
mg on the first	7
and torsadogenic potential of	7
infection and disease in	7
the quality of the	7
rr of total aes	7
and its hydroxyl analogue	7
of the two drugs	7
efficacy of these drugs	7
for assessing risk of	7
the context of a	7
los pacientes que recibieron	7
approved compound library identifies	7
with short courses of	7
cq hcq in covid	7
hydroxychloroquine and tocilizumab therapy	7
trial observational study of	7
the middle east respiratory	7
clinical trial no evidence	7
possible mechanisms of action	7
despite the lack of	7
feline infectious peritonitis virus	7
of chloroquine and covid	7
mg once daily for	7
to standard of care	7
then mg daily for	7
recommendations for the management	7
potential conflict of interest	7
the prevention and treatment	7
of possible pharmacotherapies for	7
autoimmune diseases such as	7
by interfering with the	7
did not involve human	7
enhanced by dendritic cell	7
based on in vitro	7
of hydroxychloroquine reduces fatality	7
en el momento de	7
who were treated with	7
has not been reported	7
of drug treatment on	7
should not be used	7
eular recommendations for the	7
reduces fatality of critically	7
the course of the	7
epub ahead of print	7
a significant increase in	7
in patients with chronic	7
coronavirus of probable bat	7
a copy of this	7
use of hydroxychloroquine for	7
infection in patients with	7
of rheumatoid arthritis and	7
and validation of a	7
would like to thank	7
or hydroxychloroquine as used	7
have also been reported	7
dose of mg day	7
recommendations on screening for	7
effect of cq on	7
inhibition of human immunodeficiency	7
review with a special	7
the risk of adverse	7
the effects of hydroxychloroquine	7
and acute respiratory distress	7
which is involved in	7
studies included in the	7
hydroxychloroquine reduces fatality of	7
derivatives with antimalarial and	7
both hcq and cq	7
unidades de cuidados intensivos	7
para la toma de	7
drug for the treatment	7
of chloroquine and its	7
low dose of hydroxychloroquine	7
mechanism of action is	7
to hcq and cq	7
of probable bat origin	7
and pharmacological properties of	7
to a lesser extent	7
teniendo en cuenta la	7
submit your manuscript www	7
and middle east respiratory	7
hydroxychloroquine and chloroquine in	7
for the treatment and	7
with antimalarial and antiviral	7
is still not clear	7
torsadogenic potential of possible	7
against severe acute respiratory	7
the objective of this	7
in rheumatoid arthritis patients	7
chinese center for disease	7
to an increase in	7
the hcq group and	7
spike glycoprotein and enhanced	7
and clinical characteristics of	7
association of hcq with	7
patients with type diabetes	7
but not in the	7
has been proposed as	7
of cq hcq against	7
screening of an fda	7
prolong the qt interval	7
human organic anion transporting	7
new coronavirus of probable	7
of the included reviews	7
more common in the	7
have been associated with	7
of patients from wuhan	7
cq and hcq use	7
hydroxychloroquine as used in	7
human influenza a virus	7
during the course of	7
authors declare no conflict	7
courses of chloroquine or	7
as used in covid	7
of the s protein	7
for early treatment of	7
en el de los	7
hcq has been shown	7
diseases such as rheumatoid	7
approved for the treatment	7
who did not receive	7
hoc analysis revealed that	7
determined to be exempt	7
by the institutional review	7
followed by mg bid	7
chloroquine or hydroxychloroquine as	7
el manejo de pacientes	7
the proportion of patients	6
of the spike protein	6
de los pacientes y	6
increase in the risk	6
chloroquine diphosphate in two	6
induced qtc prolongation in	6
the control group in	6
during treatment of rheumatic	6
different dosages as adjunctive	6
significantly lower than that	6
were performed using the	6
effects of hydroxychloroquine and	6
in combination with a	6
dexamethasone in hospitalized patients	6
chloroquine or hydroxychloroquine for	6
exempt from broad irb	6
of patients with a	6
the risk of bias	6
for any of the	6
the creative commons attribution	6
fungal and viral infections	6
in qtc from baseline	6
was associated with lower	6
to be exempt from	6
patients admitted to the	6
significantly inhibited by hcq	6
low risk of bias	6
the integrity of the	6
was significantly inhibited by	6
the addition of hcq	6
los servicios de salud	6
preliminary results from a	6
in vitro studies have	6
hydroxychloroquine prophylaxis for covid	6
prolongation in patient with	6
and cq has been	6
may increase the risk	6
hcq has also been	6
of a report of	6
action of hydroxychloroquine as	6
effectiveness of convalescent plasma	6
hydroxychloroquine in systemic lupus	6
as an antirheumatic drug	6
del estado de conciencia	6
in adults with severe	6
in an in vitro	6
it was found that	6
gives emergency approval to	6
be one of the	6
de forma rutinaria la	6
prior to initiation of	6
mediated by the viral	6
associated with a significant	6
signalling pathways by targeting	6
any of the icd	6
trial hydroxychloroquine in patients	6
by the severe acute	6
on virus entry and	6
to support the use	6
on the surface of	6
medrxiv preprint is the	6
cq hcq alone or	6
of hcq use in	6
in use for the	6
dose of mg kg	6
remdesivir in adults with	6
be related to the	6
a scientific statement from	6
of hcq combined with	6
influenza a virus replication	6
se recomienda realizar la	6
the need for mechanical	6
and in vivo studies	6
less toxic than cq	6
in the time of	6
the hippocampus and amygdala	6
cases from the chinese	6
treated with hcq azm	6
of hydroxychloroquine as an	6
as adjunctive therapy of	6
threatening severe qtc prolongation	6
time to clinical recovery	6
hydroxychloroquine in nonhospitalized adults	6
of hcq for the	6
in a rat model	6
retrospective cohort study of	6
the risk of cardiovascular	6
from malaria to autoimmunity	6
in the midst of	6
significantly lower in the	6
risk score to predict	6
management of severe acute	6
in nonhospitalized adults with	6
del paciente con sospecha	6
a lower risk of	6
treatment options for covid	6
severe qtc prolongation in	6
in new york city	6
use of other qt	6
patients treated by hcq	6
group was significantly lower	6
of major congenital malformations	6
management of critically ill	6
with hcq with or	6
of cases from the	6
withdrawals due to aes	6
adults with coronavirus disease	6
of hydroxychloroquine for covid	6
action of chloroquine and	6
and efficacy of hydroxychloroquine	6
for connective tissue diseases	6
was assessed using the	6
that there is no	6
the management of critically	6
have shown that hcq	6
the prophylactic role of	6
on screening for chloroquine	6
of spike glycoprotein of	6
has been demonstrated to	6
in supplementary table s	6
in critically ill covid	6
summary of a report	6
activity of chloroquine against	6
evaluate the effect of	6
and outcomes of patients	6
of hydroxychloroquine in covid	6
a high risk of	6
of these drugs as	6
erythematosus due to hydroxychloroquine	6
population pharmacokinetics of hydroxychloroquine	6
fipv replication was significantly	6
analysis was performed using	6
treated with a combination	6
in patient with systemic	6
our study was not	6
due to lack of	6
once daily for days	6
with severe respiratory syndrome	6
drug treatment on the	6
new england institutional review	6
results from a multi	6
the lack of a	6
lupus erythematosus due to	6
the number of nsaids	6
patients at risk for	6
in the range of	6
in vitro activity of	6
or hcq with or	6
by hcq and rfifn	6
a small number of	6
para el manejo del	6
hydroxychloroquine as an antirheumatic	6
as this research project	6
to clinical improvement in	6
spike glycoprotein of sars	6
the treatment of several	6
all authors have declared	6
and chloroquine during treatment	6
low molecular weight heparin	6
are included in the	6
diphosphate in two different	6
in two different dosages	6
mg dos veces al	6
effect of cq hcq	6
model of antiphospholipid syndrome	6
crh in the hippocampus	6
authors would like to	6
little is known about	6
fusion of the viral	6
in the in vivo	6
from the chinese center	6
evidence for the use	6
mortality due to covid	6
is required for the	6
de estancia en uci	6
statistical analysis was performed	6
of these drugs for	6
as a prophylactic drug	6
with acute respiratory failure	6
these drugs strongly decreased	6
targeting endosomal nadph oxidase	6
with standard of care	6
of the coronavirus disease	6
of the study population	6
nonhospitalized adults with early	6
screening for chloroquine and	6
chloroquine for influenza prevention	6
approval to hydroxychloroquine despite	6
rheumatic diseases treated with	6
systematic review and metaanalysis	6
severe respiratory syndrome in	6
qtc prolongation in patient	6
the course of disease	6
drugs strongly decreased the	6
randomized controlled trial of	6
from broad irb approval	6
and its clinical implications	6
pathways by targeting endosomal	6
may be related to	6
innate and adaptive immune	6
the american heart association	6
against malaria caused by	6
en el contexto de	6
se recomienda el uso	6
case of novel coronavirus	6
vitro inhibition of human	6
assess the impact of	6
an emergency use authorization	6
was a significant effect	6
lpv r or hcq	6
clinical trials for the	6
involve human subject research	6
experience with hydroxychloroquine and	6
in different types of	6
known to prolong the	6
of hcq for covid	6
of critically ill adults	6
cq and hcq were	6
england institutional review board	6
not involve human subject	6
in the critically ill	6
novel coronavirus in the	6
the safety of the	6
by mg bid for	6
standard of care alone	6
activity of cq and	6
clinically significant qtc prolongation	6
inhibition of human influenza	6
project did not involve	6
first case of novel	6
viral shedding duration was	6
patients admitted with covid	6
randomized clinical trial no	6
were shown to be	6
in hospitalised patients with	6
systemic lupus erythematosus due	6
of the effects of	6
la calidad de vida	6
associated with acute respiratory	6
replication was significantly inhibited	6
patients with t d	6
of the patients treated	6
in view of the	6
risk of selection bias	6
malaria caused by plasmodium	6
an observational cohort study	6
for the development of	6
can be used as	6
hydroxychloroquine or chloroquine for	6
no significant differences between	6
cells in systemic lupus	6
inhibits proinflammatory signalling pathways	6
a role in the	6
assess the efficacy of	6
were added to the	6
report of cases from	6
syndrome in the context	6
treatment on the expression	6
the production of pro	6
convalescent plasma therapy in	6
the association of hcq	6
clinical management of covid	6
emergency approval to hydroxychloroquine	6
of a novel coronavirus	6
with respect to the	6
decreased the replication of	6
processing of flavivirus prm	6
the patients in the	6
treated with cq and	6
in the face of	6
whether or not combined	6
qtc prolongation in covid	6
it is necessary to	6
significant differences in the	6
properties of hydroxychloroquine and	6
hydroxychloroquine and azithromycin for	6
dosing in intensive care	6
and hcq in the	6
research project did not	6
the novel coronavirus sars	6
than those in the	6
clinical management of severe	6
in the outpatient setting	6
at increased risk of	6
the context of coronavirus	6
protein levels of fipv	6
antiviral activity of chloroquine	6
we would like to	6
to evaluate the effect	6
therapy of hospitalized patients	6
chloroquine and hydroxychloroquine retinopathy	6
hcq combined with azithromycin	6
strongly decreased the replication	6
data of patients from	6
hcq use in covid	6
and hydroxychloroquine for the	6
clinical implications in chemoprophylaxis	6
risk of transfer to	6
authors have declared that	6
caused by plasmodium vivax	6
in time to clinical	6
preprint is the author	6
two different dosages as	6
the heart rhythm society	6
the management of the	6
twice a day for	6
infection prevention and control	6
de dificultad respiratoria aguda	6
the evidence for the	6
adverse effects associated with	6
and its immune cross	6
a small sample size	6
ministerio de salud y	6
no statistically significant difference	6
have shown that the	6
to hydroxychloroquine despite lack	6
be exempt from broad	6
especially in patients with	6
its clinical implications in	6
for the overall effect	6
mg bid for days	6
pacientes hospitalizados con covid	6
and the number of	6
us gives emergency approval	6
was identified as a	6
of hydroxychloroquine or chloroquine	6
in order to evaluate	6
days in patients with	6
clinical trials are currently	6
of hcq as a	6
hydroxychloroquine inhibits proinflammatory signalling	6
of observational studies in	6
the ph of acidic	6
of randomized controlled trials	6
hcq and cq has	6
important role in the	6
hydroxychloroquine and its clinical	6
was not significantly different	6
received hcq based treatment	6
in the st century	6
for acute respiratory distress	6
involved in the metabolism	6
in severe acute respiratory	6
manejo de pacientes con	6
in chemoprophylaxis against malaria	6
we were able to	6
antiviral effects of the	6
are weak bases that	6
characterization of spike glycoprotein	6
of the left foot	6
treatment with hcq and	6
approved drug ivermectin inhibits	6
the use of a	6
health commission of guangdong	6
proteolytic processing of flavivirus	6
chloroquine during treatment of	6
was obtained from the	6
the total number of	6
of the novel coronavirus	6
the lancet infectious diseases	6
entry and its immune	6
of flavivirus prm protein	6
on the management of	6
or standard of care	6
have been used in	6
intensive care unit covid	6
dorsum of the left	6
scientific statement from the	6
patients in the united	6
significant effect of hcq	6
of hcq or cq	6
for the prevention and	6
risk factors associated with	6
studies have been conducted	6
a series of patients	6
respiratory syndrome in the	6
in the qtc interval	6
mg bid for d	6
use in patients with	6
the small number of	6
towards optimization of hydroxychloroquine	6
treated with hcq with	6
commission of guangdong province	6
followed by mg once	6
both in vitro and	6
the primary outcome of	6
proinflammatory signalling pathways by	6
hydroxychloroquine despite lack of	6
dosages as adjunctive therapy	6
adjunctive therapy of hospitalized	6
was also observed in	6
of the creative commons	6
medicine and infectious disease	6
authorization for use of	6
has been identified as	6
et al reported that	6
adults with early covid	6
severe acute respiratory infection	6
travel medicine and infectious	6
virus entry and its	6
con el objetivo de	6
cardiac side effects of	6
and supplementary table s	6
in a series of	6
treatment of adults with	6
compared to those who	6
approved by the institutional	6
cleavage of the s	6
also been reported to	6
evaluate the efficacy of	6
both prophylactic and therapeutic	6
the time of covid	6
of hydroxychloroquine dosing in	6
of the patients in	6
en pacientes hospitalizados con	6
both serotypes of fipv	6
at a higher risk	6
severe cases of covid	6
chemoprophylaxis against malaria caused	6
regarding the use of	6
hydroxychloroquine dosing in intensive	6
at the site of	6
al momento de la	6
the primary outcome was	6
play a role in	6
disease as well as	6
the mean age was	6
this research project did	6
a summary of the	6
a virus replication by	6
using a combination of	6
issued an emergency use	6
the patients treated with	6
for both cq and	6
de pacientes con sospecha	6
of patients admitted to	6
complications in patients with	6
are shown in table	6
in the lpv r	6
implications in chemoprophylaxis against	6
and viral infections in	6
the inhibition of the	6
the current knowledge on	6
use authorization for use	6
an analysis of data	6
by targeting endosomal nadph	6
inhibited ebola virus replication	5
and its derivative hydroxychloroquine	5
procedimiento generador de aerosoles	5
un procedimiento generador de	5
treated with hcq monotherapy	5
chloroquine and hydroxychloroquine on	5
what every clinician should	5
hydroxychloroquine for prophylaxis of	5
all conditions were tested	5
el retiro de la	5
en tiempos de pandemia	5
for suspected cases of	5
to the original author	5
interfering with the glycosylation	5
east respiratory syndrome and	5
species severe acute respiratory	5
with a history of	5
disease in the in	5
de pointes and sudden	5
the active site residues	5
safety of hydroxychloroquine in	5
the course of covid	5
be used as a	5
in hospitals in france	5
and the possibility of	5
conditions were tested in	5
for the diagnosis of	5
of fatal outcomes of	5
the images or other	5
the risk of death	5
be inhibited by cq	5
viral clearance compared to	5
an important role in	5
mg once daily on	5
hcq have been shown	5
from months before the	5
patients with connective tissue	5
response relationships in patients	5
of novel coronavirus in	5
a wide spectrum of	5
of the risk of	5
article distributed under the	5
in relation to covid	5
protect against infection and	5
sample size of the	5
retrospective matched cohort study	5
patients with inflammatory arthritis	5
severe acute respiratory infections	5
se recomienda en pacientes	5
replication in vitro but	5
was observed between the	5
regulation or exceeds the	5
a large volume of	5
rheumatoid arthritis and related	5
to treat autoimmune diseases	5
any medium or format	5
effects of these drugs	5
de wilde et al	5
sulfate supplied from the	5
implications of fatal outcomes	5
evidence does not support	5
in the production of	5
and critique of the	5
camas de cuidados intensivos	5
a reduction in the	5
unless indicated otherwise in	5
college of cardiology foundation	5
might be due to	5
the number of patients	5
therapy and pharmacological properties	5
on the cardiovascular system	5
the binding of the	5
chloroquine in treatment of	5
who received hcq with	5
to protect against infection	5
and shortness of breath	5
in a murine model	5
association of cardiac injury	5
single oral dose of	5
prolongation in hospitalized patients	5
study is limited by	5
use of lopinavir ritonavir	5
prolongation of qt interval	5
with hydroxychloroquine azithromycin and	5
patients with significant arrhythmias	5
with hcq and rfifn	5
received hcq with or	5
chloroquine for the novel	5
has been observed in	5
since there is a	5
or other third party	5
licensed under a creative	5
dosing for patients with	5
the first day of	5
hospitalised patients with covid	5
added to the cells	5
increased mortality associated with	5
the absence of any	5
has been presented in	5
inhibit proteolytic processing of	5
and azithromycin for suspected	5
by statutory regulation or	5
in moderate to severe	5
not combined with hcq	5
of adults with mild	5
with lower mortality in	5
and clinical cure in	5
it was observed that	5
no potential conflict of	5
and mechanism of action	5
to the creative commons	5
for the prevention or	5
the mean age of	5
induced qt prolongation and	5
macrophages by different modes	5
a crucial role in	5
the clinical course of	5
using cq and hcq	5
epidemiology of novel coronavirus	5
with ra and sle	5
a risk factor for	5
phase of the disease	5
hcq with a macrolide	5
hydroxychloroquine as a treatment	5
polymorphisms of cytochrome p	5
treatment of malaria and	5
uncoating of influenza b	5
higher risk of mortality	5
a broad spectrum of	5
and severity of illness	5
pointes in hospital settings	5
to treat malaria and	5
way anova indicated that	5
cells through a novel	5
among patients hospitalized with	5
and time in icu	5
other regimens in marseille	5
medrxiv preprint all rights	5
from the vena cava	5
is associated with lower	5
beginning of the pandemic	5
new directions of uses	5
as you give appropriate	5
this study is limited	5
at least in part	5
in patients with non	5
to evaluate the efficacy	5
line to the material	5
was significantly lower in	5
the positive effect model	5
antiviral effects of hcq	5
performed in order to	5
torsades de pointes and	5
to be more effective	5
effect of hcq is	5
than that in the	5
at the media briefing	5
treatment of people with	5
treatment of covid infection	5
reported in the original	5
was involved in the	5
of adverse events in	5
the hcq arm of	5
in patients with type	5
of heterogeneity accounted for	5
for treatment of coronavirus	5
and toxic manifestations from	5
grade ventricular arrhythmias were	5
avian influenza a h	5
against infection and disease	5
first case of covid	5
world evidence from a	5
in any medium or	5
appropriate credit to the	5
of chloroquine in the	5
and randomized clinical trials	5
hydroxychloroquine azithromycin and other	5
in a model of	5
azithromycin and other regimens	5
ill patients with sars	5
as can be seen	5
forma rutinaria el uso	5
arm of the solidarity	5
those who did not	5
for a long time	5
den borne et al	5
and the need for	5
number of patients with	5
as well as its	5
hydroxychloroquine levels in patients	5
cardiovascular implications of fatal	5
with mild moderate covid	5
association of polymorphisms of	5
to the host cell	5
of infection in patients	5
admission and mechanical ventilation	5
statement from the american	5
therapeutic efficacy of the	5
of this drug is	5
approach for effective drug	5
the clinical effectiveness of	5
accepted article this article	5
to obtain permission directly	5
of human coronavirus e	5
from the copyright holder	5
in the liver and	5
reveal a new mechanism	5
the locomotor activity of	5
is used in the	5
to an increased risk	5
hydroxychloroquine treatment among hospitalized	5
you will need to	5
from the american heart	5
of the study was	5
for qt interval monitoring	5
predictors of mortality due	5
use in the treatment	5
this article is licensed	5
that there was a	5
in the treatment or	5
in treatment of systemic	5
the baseline qtc was	5
the amount of heterogeneity	5
than in the pbs	5
de la enfermedad y	5
of polymorphisms of cytochrome	5
article are included in	5
hydroxyl analogue to face	5
statistical evidence for the	5
extracorporeal membrane oxygenation for	5
glycosylation of the ace	5
the treatment of people	5
the use of this	5
of herpes simplex virus	5
los pacientes con sdra	5
indian council of medical	5
is a lack of	5
for chloroquine in the	5
that hcq and cq	5
de servicios de salud	5
in the hcq arm	5
guangdong province for chloroquine	5
of the prophylactic role	5
the cq and hcq	5
significantly higher proportion of	5
of cases of novel	5
use of hydroxychloroquine or	5
is the first study	5
higher risk of cardiac	5
is known to be	5
the case of sars	5
chloroquine phosphate or hydroxychloroquine	5
in patients treated by	5
a greater risk of	5
there were no instances	5
caution should be taken	5
view a copy of	5
a higher rate of	5
been found to be	5
inhibits production of tnf	5
the onset of symptoms	5
suspected cases of covid	5
images or other third	5
discharge in patients hospitalized	5
cases of novel coronavirus	5
amongst hcq users in	5
infection in vitro chloroquine	5
started late in the	5
in vivo guinea pig	5
the findings of this	5
with suspected or confirmed	5
remarks at the media	5
there is no evidence	5
malaria to multifarious diseases	5
who received hcq based	5
if material is not	5
concomitant qt prolonging medications	5
human coronavirus oc infection	5
is based on the	5
american academy of ophthalmology	5
hydroxychloroquine dosing for patients	5
late in the disease	5
in agreement with the	5
the efficacy of either	5
found no evidence of	5
and safety of these	5
the terminal glycosylation of	5
supplied from the strategic	5
diseases society of america	5
chloroquine in patients with	5
there was no difference	5
see supplementary table s	5
the risk of transfer	5
for inhibition of sars	5
tratamiento de soporte vital	5
cq and hcq can	5
hcq arm of the	5
adverse events associated with	5
stimulator of interferon genes	5
adverse effects of hcq	5
relationships in patients with	5
the prevention of covid	5
chloroquine analogues in drug	5
modifying antirheumatic drugs and	5
it has been suggested	5
blood hydroxychloroquine levels in	5
d with blood hydroxychloroquine	5
we were unable to	5
mg kg per day	5
in combination with az	5
treated with mg kg	5
critique of the manuscript	5
cytokines such as il	5
institutional review board of	5
em structure of the	5
was defined as any	5
of this article is	5
safety profile of hcq	5
receiving hcq with or	5
monocytes macrophages by different	5
viral load in the	5
to reduce the mortality	5
foundation for statistical computing	5
anova indicated that there	5
indicated that there was	5
study observational study of	5
more potent than cq	5
sars coronavirus entry into	5
inflammation and endothelial dysfunction	5
analogue to face bacterial	5
novel coronavirus pneumonia in	5
can be seen in	5
or prevention of covid	5
need to obtain permission	5
virological and clinical cure	5
or need for mechanical	5
the relationship between hcq	5
without azithromycin and in	5
or discharge in patients	5
an in vitro study	5
test for the overall	5
is not permitted by	5
chloroquine inhibited ebola virus	5
sensitive to the assumptions	5
factors associated with qtc	5
the viral load in	5
a cohort study of	5
la cabecera del paciente	5
exceeds the permitted use	5
included in the analysis	5
large number of patients	5
plays a key role	5
and or hcq in	5
empirical treatment with hydroxychloroquine	5
magnitude of qtc prolongation	5
a favor fundamento la	5
un total de pacientes	5
el tratamiento de pacientes	5
with middle east respiratory	5
en cuanto a la	5
dentro de las primeras	5
a public health emergency	5
have been widely used	5
the upper respiratory tract	5
of hcq did not	5
of mortality due to	5
the authors would like	5
of hydroxychloroquine treatment among	5
have the potential to	5
reduction in the risk	5
factors associated with acute	5
hydroxychloroquine for early treatment	5
indicated otherwise in a	5
new mechanism of action	5
as prophylaxis for sars	5
article this article is	5
have a protective effect	5
and your intended use	5
credit to the original	5
systemic lupus erythematosus under	5
other third party material	5
onset of symptoms and	5
coronavirus pneumonia in wuhan	5
failed to protect against	5
further studies are needed	5
the treatment or prevention	5
hcq is associated with	5
life threatening severe qtc	5
hcq appears to be	5
in patients with t	5
cardiac injury with mortality	5
epidemiological and clinical characteristics	5
a limited number of	5
on immune activation and	5
was not possible to	5
of chloroquine against human	5
para el personal de	5
material is not included	5
toxic manifestations from malaria	5
con ic al de	5
de los elementos de	5
article is licensed under	5
in combination with azm	5
the treatment and control	5
de forma rutinaria el	5
to initiation of hcq	5
obtain permission directly from	5
hasta el momento no	5
one of the first	5
for prophylaxis of sars	5
due to adverse effects	5
were obtained from the	5
p d with blood	5
chloroquine inhibits production of	5
permitted by statutory regulation	5
days of symptom onset	5
there is a lack	5
these drugs in covid	5
and hydroxychloroquine against sars	5
cq or hcq is	5
long as you give	5
analysis of data of	5
the majority of the	5
for the duration of	5
on the prognosis of	5
the findings of the	5
of feline infectious peritonitis	5
used to assess the	5
reportaron una serie de	5
can be found in	5
accounted for in the	5
the methodological quality of	5
qtc from baseline of	5
use of tocilizumab in	5
to be related to	5
a code for a	5
ncov and naming it	5
the treatment with hcq	5
is an antimalarial drug	5
en los servicios de	5
with blood hydroxychloroquine levels	5
be explained by the	5
infection in hospitals in	5
tocilizumab in patients with	5
from the strategic national	5
were no instances of	5
the antimalarial drug chloroquine	5
fatal outcomes of patients	5
admission to the intensive	5
study was approved by	5
distributed under the terms	5
used as a treatment	5
will need to obtain	5
la gravedad de la	5
credit line to the	5
vitro but failed to	5
included in this analysis	5
a beneficial effect of	5
acidotropic amines inhibit proteolytic	5
that both cq and	5
safety of these drugs	5
r foundation for statistical	5
risk of exposure to	5
the association between hcq	5
treatment of critically ill	5
cytochrome p d with	5
not permitted by statutory	5
hcq and az in	5
against human coronavirus oc	5
significantly decreased in the	5
of hydroxychloroquine treatment on	5
cq with a macrolide	5
three times daily for	5
in the treatment and	5
and its impact on	5
el personal de salud	5
high morbidity and mortality	5
of discharge home were	5
similar to that of	5
of hydroxychloroquine use with	5
congenital malformations associated with	5
adjusted for age and	5
the effects of chloroquine	5
been proposed as a	5
under a creative commons	5
it is still not	5
disminuir el riesgo de	5
en los que se	5
ill adults with coronavirus	5
study was conducted in	5
d interaction diagrams of	5
patients treated with either	5
the active site of	5
clinical trials are ongoing	5
every clinician should know	5
for prophylaxis and treatment	5
icu admission and mechanical	5
the robustness of the	5
pharmacotherapies for coronavirus disease	5
modeling approach for effective	5
of doxycycline and hcq	5
mortality or discharge in	5
a prophylactic drug against	5
coronavirus entry into host	5
directly from the copyright	5
antimalarial drugs inhibit ifn	5
that the mrna expression	5
the authors concluded that	5
library identifies four small	5
la bolsa de residuos	5
among patients who received	5
give appropriate credit to	5
with mortality in hospitalized	5
inflammatory cytokines such as	5
have been reported to	5
effects of hcq in	5
in the early stages	5
the discretion of the	5
the aim of this	5
as long as you	5
and environment for statistical	5
provide a link to	5
rates of discharge home	5
of hospital stay and	5
intended use is not	5
factores de riesgo cardiovasculares	5
trial a pilot study	5
cq and hcq to	5
a credit line to	5
use of these medications	5
a study of patients	5
cq has been reported	5
the united states and	5
infectious diseases society of	5
teniendo en cuenta que	5
de pointes in hospital	5
azithromycin and the risk	5
its hydroxyl analogue to	5
did not receive hcq	5
cohort of patients with	5
have been reported in	5
a new mechanism of	5
o en contra para	5
to that of the	5
were more common in	5
the side effects of	5
review of the prophylactic	5
viral infections in the	5
outcomes of hydroxychloroquine treatment	5
in vitro but failed	5
the antimalarial drugs chloroquine	5
it is worth noting	5
our study has several	5
cq hcq have been	5
the species severe acute	5
higher risk of adverse	5
the transmission of the	5
in an animal model	5
hospital mortality or discharge	5
as potential treatment for	5
to account for the	5
of these drugs to	5
it was not possible	5
prophylactic role of chloroquine	5
preprint all rights reserved	5
el ministerio de salud	5
for the original data	5
the change in qtc	5
it is likely that	5
be due to the	5
use of chloroquine phosphate	5
lung tissue and elf	5
and disease in the	5
chloroquine and hydroxychloroquine against	5
in this article are	5
than the control group	5
of acute respiratory distress	5
resolution of fever and	5
of patients receiving hcq	5
link to the creative	5
the expression of bdnf	5
prevention of torsade de	5
stay and time in	5
province for chloroquine in	5
mouse model of antiphospholipid	5
used in this study	5
and the fact that	5
hcq and azithromycin and	5
with connective tissue diseases	5
effectiveness and safety of	5
with rheumatoid arthritis and	5
pacientes con falla renal	5
a median age of	5
injury with mortality in	5
in vitro ec values	5
adults with mild covid	5
or arrhythmic cardiac arrest	5
a single oral dose	5
a link to the	5
azithromycin in the covid	5
is associated with increased	5
of both serotypes of	5
have been used for	5
discharge home were observed	5
a positive pcr test	5